VEGFR-1 Inhibitors Market Size is predicted to grow at a 7.0% CAGR during the forecast period for 2024-2031.
VEGFR-1 inhibitors are essential in treating various cancers by targeting the vascular endothelial growth factor receptor-1, which is crucial for angiogenesis and tumor growth. The increasing prevalence of cancer and advancements in targeted therapies are expected to drive the adoption of VEGFR-1 inhibitors. Additionally, ongoing research, regulatory approvals, and rising healthcare expenditure are anticipated to propel market growth. However, high treatment costs and potential side effects could restrain market expansion.
The most common types of cancer include colon and rectum, leukemia, prostate, breast, lung, bronchus, melanoma, kidney and renal pelvis, and pancreatic cancer. These factors contribute to the market's growth. However, the side effects associated with these inhibitors could limit market expansion during the forecast period. Side effects of these inhibitors include hypertension, stroke or heart attack, reversible posterior leukoencephalopathy syndrome, impaired wound healing, and protein in the urine.
Competitive Landscape
Some of the Major Key Players in the VEGFR-1 Inhibitors Market are
- Eisai Co., Ltd.
- Merck & Co., Inc.
- Advenchen Laboratories, LLC
- Sino Biopharmaceutical Limited
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Exelixis, Inc.
- Ipsen S.A.
- Pfizer Inc.
- Hutchison China MediTech Limited (Hutchmed)
- Mirati Therapeutics, Inc.
- Eli Lilly and Company
- Clovis Oncology, Inc.
- Les Laboratoires Servier (Servier)
- Pharma Mar, S.A.
- F. Hoffmann-La Roche AG (Roche)
- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen)
- Teva Pharmaceutical Industries Ltd.
Market Segmentation:
The VEGFR-1 inhibitors market is segmented by drug type, application, and distribution channel. By drug type, the market includes monoclonal antibodies, tyrosine kinase inhibitors, and other drug types. By application, the market is divided into renal cell carcinoma, colorectal cancer, non-small cell lung cancer, and other applications. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies.
Monoclonal Antibodies Are A Major Contributor In The VEGFR-1 Inhibitors Market.
The monoclonal antibodies segment is expected to hold a significant share of the global VEGFR-1 inhibitors market in 2021, attributed to their high specificity and effectiveness in targeting cancer cells while minimizing harm to normal cells. Increasing approvals and clinical trials of monoclonal antibodies are further boosting their market growth.
The Non-Small Cell Lung Cancer Segment Is Growing Rapidly.
The non-small cell lung cancer segment is projected to grow at a rapid rate due to the high prevalence of lung cancer and the increasing use of targeted therapies. The rising incidence of smoking-related cancers and advancements in lung cancer treatments are driving this segment's growth.
North America Leads The VEGFR-1 Inhibitors Market In Terms Of Revenue.
North America is expected to dominate the VEGFR-1 inhibitors market in terms of revenue, due to its well-established healthcare infrastructure, high cancer prevalence, and substantial R&D investments. Additionally, the presence of major pharmaceutical companies and favorable regulatory policies support market growth. The Asia-Pacific region is projected to experience rapid growth due to increasing healthcare awareness, improving healthcare facilities, and a growing patient population.
Recent Developments:
- In January 2022, Pfizer Inc. received FDA approval for a new VEGFR-1 inhibitor for the treatment of advanced renal cell carcinoma.
- In March 2023, Novartis AG announced positive results from a phase III clinical trial of its investigational VEGFR-1 inhibitor for the treatment of non-small cell lung cancer.
VEGFR-1 Inhibitors Market Report Scope
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 7.0% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Type, By Application, By Distribution Channel and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Eisai Co., Ltd., Merck & Co., Inc., Advenchen Laboratories, LLC, Sino Biopharmaceutical Limited, Novartis AG, Takeda Pharmaceutical Company Limited, Exelixis, Inc., Ipsen S.A., Pfizer Inc., Hutchison China MediTech Limited (Hutchmed), Mirati Therapeutics, Inc., Eli Lilly and Company, Clovis Oncology, Inc., Les Laboratoires Servier (Servier), Pharma Mar, S.A., F. Hoffmann-La Roche AG (Roche), Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen), and Teva Pharmaceutical Industries Ltd. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
